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Introduction
Of the many diseases associated with infection by the proto-
zoan parasite Leishmania, visceral leishmaniasis (VL) represents 
one of the most challenging to understand in terms of its patho-
physiology. Unlike cutaneous leishmaniasis, where parasite 
growth and the pathological consequences of the ensuing immune 
response are largely confined to the site of transmission, VL 
is characterized by systemic spread of parasites, multi-organ 
involvement and a systemic response that is fatal without treat-
ment. Systemic cytokine mediated immunosuppression1,2, T cell 
functional defects3–7, alterations to the structural integrity of 
the lymphoid tissue8–10 and systemic coagulopathies11,12 have 
all been proposed as mechanisms that promote parasite survival, 
render the host susceptible to concomitant secondary infec-
tions and/or act as negative prognostic markers. Evidence from 
animal models suggests that tissue specific control over 
immunity and immunopathology also exists, that may in part 
reflect extremes within the clinical spectrum of VL13,14. In spite 
of the broad impact of infection on a range of key physiologi-
cal processes, a systems-wide appreciation of the underlying 
immune, metabolic and physiological changes associated with 
VL has yet to emerge.
Over the past several years, transcriptomic profiling has been 
adopted as a key methodology for generating an unbiased 
view of many disease processes. The application of tran-
scriptomic profiling has provided valuable insights into the 
pathogenesis of many infectious and non-infectious diseases15–26, 
and on the response to drugs, vaccines and other immunothera-
peutic interventions27–31. From a clinical perspective, the appli-
cation of whole blood transcriptomic profiling (WBTP) opened 
a new era in clinical monitoring of disease, fuelled notably 
by the work of Chaussebel and others that illustrated its potential 
to provide insights into systemic disease processes and serve 
as a clinical tool19,32–34. Nevertheless, whether WBTP provides 
information reflecting a subset of systemic events or is an avatar 
of that response remains to be fully determined. Indeed, stud-
ies formally comparing whole blood with the systemic tissue 
transcriptome are rare21.
Transcriptomic profiling in leishmaniasis has been limited to 
date. In human disease, this has largely focused on cutaneous 
leishmaniasis35–37. A single study has reported on transcrip-
tional changes in the draining lymph node of Sudanese patients 
with VL before and after treatment with sodium stibogluco-
nate, identifying a potential role for nuclear factor of activated 
T cells (NFAT)-regulated immune responses in treatment 
response38. One study has examined whole blood transcrip-
tional responses in healthy controls versus asymptomatic and 
symptomatic VL patients in Brazil39. Three studies have evalu-
ated transcriptional changes in the spleen of hamsters infected 
with L. donovani40–42. Here, we have applied transcriptional 
profiling to address key aspects of the tissue specific response 
to L. donovani infection in mice. We describe key differences 
between immune response and metabolic events occurring 
in the principal target organs of liver and spleen, as well as in 
blood, and where possible through publically available data, 
provide a formal comparison between the splenic response in 
mice and hamsters and between murine and human whole blood.
Methods
Ethics statement
Experiments were approved by the Animal Welfare and Eth-
ics Review Bodies of the University of York and the LSHTM 
and the work was performed under UK Home Office license 
(PPL 60/4377; PPL 70/6997; PPL 70/8207). Mice were killed 
by cervical dislocation prior to tissue collection, as described 
below.
Mice and infections
6–8-week-old female BALB/c mice (Charles River, Margate, 
UK) weighing 20±1 gm and health screened to FELASA 67M 
standard and maintained under specific pathogen free conditions 
in individually ventilated cages were used in this study. Leishma-
nia donovani (LV9) parasites were maintained in B6. Rag1-/- mice 
and amastigotes prepared following tissue disruption, cell lysis 
and differential centrifugation, as described elsewhere43. 2r107 
amastigotes in 150 µl RPMI were injected intravenously (i.v.) via 
the lateral tail vein and without anaesthetic to initiate infection. 
After infection, mice were allocated to cages of 5 and pro-
vided food and water ad libitum. Experiments reported here are 
derived from two cohorts of mice (designated CRACK-IT_1 and 
CRACK-IT_2; 20 mice per cohort, n=5 per infection time point 
and for time-matched uninfected controls). In CRACK-IT_1, 
mice (n=5) were killed by cervical dislocation at day 15, 17 and 
21 post infection. Control naïve mice were killed on the equiva-
lent of day 14 p.i. for logistical reasons. In CRACK-IT_2, infected 
mice (n=5 per group) were killed at day 36 and 42, alongside a 
control naïve group. All animals were killed and processed 
over an approximate time period of 4–6h beginning in the 
morning. Tissues were aseptically removed post mortem and 
stored/processed as detailed below. All downstream tissue 
analysis was performed blinded to group by investigators not 
involved in animal handling.
Histology and quantitative morphometry
Spleens and livers were embedded in OCT, snap frozen and 
stored at -80°, before preparing 7 µm cryosections. All 
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subsequent steps were carried out at room temperature. For gross 
morphology, sections were fixed for 5 minutes in ice-cold ace-
tone and rehydrated by immersion for 2–3 minutes in 90% etha-
nol, 70% ethanol and finally ddH2O. Sections were transferred to 
Harris’s haematoxylin (Sigma-Aldrich, UK) for 5 minutes, then 
‘blued’ in running tap water for 5 minutes. Slides were differen-
tiated using 1% acid alcohol for 5 seconds, washed in tap water 
for 3minutes and stained with 1% w/v eosin (Sigma-Aldrich, 
UK) in distilled water for 3 minutes. Slides were washed for 
3 minutes in ddH2O and dehydrated through alcohols, cleared 
in Xylene and mounted in DPX.
For immunohistochemistry, sections were fixed for 5 minutes 
in ice cold acetone and rehydrated for 2 x 5 minutes in wash 
buffer (0.05% w/v BSA in PBS) and blocked for 30 minutes in 
dilution buffer (5% v/v goat serum in wash buffer). After 
washing, sections were stained for 45 min with AlexaFlour 
647-F4/80 or isotype control (BioLegend, USA; 1:500), 
counterstained with DAPI and mounted in Prolong Gold. 
Sections were examined using a Zeiss Axio Scan Z1 with 
a x 20 objective. Granuloma size and distribution was quantified 
using image analysis software TissueQuest 4.0 (TissueGnostics, 
Vienna, Austria), blind to treatment group. DAPI was used as the 
master channel to identify all events within the regions of 
interest, and clustering of F4/80+ cells was used to identify gran-
ulomas. All granulomas within a 1mm2 region of interest were 
identified as individual sub regions of interest, and size and 
cell density was recorded.
Tissue transcriptomics
RNA was isolated from tissue/blood samples and ampli-
fied via Agilent low-input Quick Amp labelling kit (Agilent 
Technologies). Amplified RNA was then assayed with Agilent 
SurePrint G3 mouse GE 8x60k microarray chips that were scanned 
with an Agilent C Scanner with Surescan High Resolution Tech-
nology (Agilent Technologies). The data were normalized using 
the percentile shift method to the 75th percentile. Identification of 
differentially expressed (DE) genes between infected and naïve 
samples was performed using the Benjamini and Hochberg false 
discovery rate (FDR) correction for pairwise comparisons of 
infected vs. naïve samples44. Where multiple probes for a single 
gene were present, the average expression level was used. This 
analysis was performed with GeneSpring software (version 9; Agi-
lent) as a standard 5% FDR, with the variances assessed by the 
software for each t test performed. A 2-fold expression criteria 
(Log2 FC = 1)was then applied to each gene list. For DE analy-
sis in CRACK-IT_1, a single group of naïve mice were killed at 
d14 for comparison with samples of infected mice taken at d15, 
d17 and d21 p.i. For CRACK-IT_2, DE analysis was performed 
using matched naïve samples for each tissue taken at each 
time point (see Results).
Gene ontology analysis was performed using GeneSpring (Agi-
lent), and pathway analysis was conducted using Ingenuity 
Pathway Analysis software (Ingenuity Systems). For the identifi-
cation of upstream regulators in IPA, we used the z score, which 
reflects the extent to which known target genes are regulated 
in the expected direction, whereby positive z scores predict 
activation of the regulator whereas negative z scores predict 
inhibition of the regulator. z scores of >2 and <-2 are considered 
significant. Gene set enrichment analysis (GSEA)34 was performed 
to identify enriched gene sets associated with each phenotype (i.e. 
infected at each time point vs. naïve). Data were collapsed to gene 
set against an Agilent mouse array chip file (~24K genes) and 
parameters set for GSEA were: permutations =1000; permutations 
type = gene set (sample n<7) or phenotype (sample n>7). Puta-
tive protein-protein interactions were identified using STRING45. 
Interferon-inducible genes were identified using Interferome 
v2.046 Non-weighted Venn diagrams were generated using 
Venny 2.147. Hamster transcriptomic datasets were from 41. Com-
parisons were made based on ENSEMBL ids and gene symbol 
and annotation was used to compare hamster / mouse orthologs. 
Human transcriptomic data sets were from 39. Weighted Venn 
diagrams were generated in R using the eulerr package (https:// 
cran.r-project.org/package=eulerr) and correlation plots were 
created using the ggplot2 package (https://cran.r-project.org/ 
web/packages/ggplot2/index.html).
Results
Splenic response to L. donovani infection in BALB/c mice
As part of a larger program of research aimed at evaluating 
multiple aspects of EVL (the CRACK IT VIDR project; see Dis-
cussion), we infected two cohorts of female BALB/c mice with 
2r107 amastigotes of L. donovani (CRACK-IT_1 and CRACK-
IT_2) and at defined time points corresponding to increased 
parasite load and architectural changes in the splenic micro-
environment (Figure 1), spleen tissues were processed for 
genome-wide transcriptomic profiling by microarray. An 
overview of the expression data is presented as volcano plots 
and heat maps for naïve mice (total n=15) and infected mice 
(total n=25) examined at each time post infection (p.i.) 
(Figure 2A and B). Some minor changes were noted in groups 
of naïve mice examined at each time point, despite confirma-
tion of comparability in age, sex, weight and health status. To 
account for these minor variations, DE genes were identi-
fied by reference to time- and experiment-matched naïve 
controls (Figure 2B). Using a mean FDR adjusted p value 
cut-off of 0.05 and a FC of 2 (Log2FC = 1) for at least 
one of the infection time points, 9634 probes were scored 
as DE across the entire time series (Table S1). The number of 
DE probes increased over time, peaking at d36 p.i. (d15: 1997 
probes, Log2FC -3.52 to +5.82; d17: 2826 probes, log2FC -
4.01 to +6.37; d21: 5124 probes, Log2FC -4.54 to +7.59; d36: 
5051 probes, Log2FC -6.45 to +8.36; d42: 4946 probes, 
Log2FC -6.30 to +7.13).
After removal of multiple probes, 5096 annotated genes were 
identified within this DE probe set across all time points 
(d15, 1078 genes; d17, 1653 genes; d21, 2880 genes; d36, 2708; 
d42, 2805). To determine if genes related to specific biological 
responses were differentially regulated over time of infection, 
we used GSEA34. As shown in Figure 3A, Table 1 and Table S2, 
the most commonly enriched gene sets across the time course 
were interferon gamma signalling, TNF signalling, myogenesis, 
allograft rejection, IL-6 – JAK/STAT signalling, angiogenesis, 
G2M checkpoint, inflammatory response, oestrogen response, 
epithelial-mesenchymal transition, E2F targets, KRAS signal-
ling and complement. Notably, the breadth of enriched pathways 
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Figure 1. Splenic response to L. donovani infection. Spleens from BALB/c mice infected with L. donovani were removed at 15-, 17-, 21-, 36- 
and 42-days post infection, along with spleens from naïve age matched controls. A. Parasite burdens were determined by impression 
smears and are represented as mean LDU ± SE (n=5 mice per time point). B. Spleen weight for naïve and infected mice (mg ± SE). 
C–H. Representative histology of spleens from naïve mice (C and D) and from d17 (E and F) and d42 (G and H) infected mice. Hematoxylin 
and Eosin x20 (C, E and G) and x40 (D, F and H); scale bars 50 µm. Blue arrows highlight parasite clusters. White dashed lines indicate red 
pulp (rp) / white pulp (wp) boundary. G and H show increased frequency of megakaryocytes, indicative of extramedullary haematopoiesis 
and loss of white pulp / red pulp discrimination. Data are pooled from two independent experiments covering the early and late phase of 
infection.
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Figure 2. Transcriptomic profiling of spleen response to L. donovani infection in BALB/c mice. A. Volcano plots showing DE probes 
at each time point of infection (relative to matched naïve control mice). Data are shown as Log2 FC in expression against Log10 adjusted 
p value. B. Heat map of probe expression intensity across time series. Data are pooled for n=5 mice per group for clarity. Vertical blue 
trace indicates mean intensity signal. Sample “naïve 0” was used to calculate DE genes for days 15, 17 and 21 p.i. Samples “naïve 36” and 
“naïve 42” were used to calculate DE genes for their respective time points p.i.
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Figure 3. Characteristics of the spleen transcriptomic response to L. donovani infection in BALB/c mice. A. Data were subjected to 
GSEA with reference to MSigDB Hallmark gene sets and normalized enrichment score over time is shown for the top 25 gene sets at any given 
time point. Days post infection are indicated by coloured dots (d15, black; d17, blue; d21, magenta; d36, brown, d42 red). B. IPA-predicted 
upstream regulators presented as a heat map based on z scores ranging from -9 (negative regulators) to +9 (positive regulators). C. IPA 
mechanistic pathway analysis indicating the 16 linked regulatory proteins, that together are predicted to regulate ~14% of all DE genes in the 
L. donovani infected spleen. Predicted relationships are indicated by lines (orange, leading to activation; blue, leading to inhibition; yellow, 
inconsistent; grey, not predicted). Box shading represents degree of predicted activation (orange) or inhibition (blue). D. Venn diagram showing 
distribution of 1645 Type I and II Interferon-induced genes, as identified using Interferome v2.01. E. Predicted Trim24 targets identified in IPA 
that show upregulated expression during infection. Predicted relationships are indicated by lines: Orange represents leading to activation; 
grey represents not predicted. Gene symbol box shading reflects extent of upregulation (red) and downregulation (green) in dataset. For an 
explanation of molecule shapes and relationship types, see http://qiagen.force.com/KnowledgeBase/articles/Basic_Technical_Q_A/Legend.
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Table 1. Summary of enriched gene sets in the spleen of L. donovani-infected BALB/c mice.
Data was subjected to GSEA against the MSigDB 
Hallmark gene set and represents a summary of the 
top 10 gene sets (by FDR) for each time point. For full 
dataset including gene lists, see S2Table. Normalised 
enrichment scores for all gene sets listed for all time 
points are shown in Figure 3A. day 15 day 17 day 21 day 36 day 42
Gene Set Name FDR q-value
HALLMARK_KRAS_SIGNALING_UP 7.80E-09 3.07E-11 2.70E-24 1.63E-20
HALLMARK_KRAS_SIGNALING_DN 2.67E-08
HALLMARK_ALLOGRAFT_REJECTION 1.15E-07 8.95E-10 9.97E-27
HALLMARK_IL6_JAK_STAT3_SIGNALING 2.48E-07
HALLMARK_INTERFERON_GAMMA_RESPONSE 2.40E-06 7.24E-26 1.07E-22 2.75E-40 1.88E-27
HALLMARK_ESTROGEN_RESPONSE_EARLY 9.16E-06
HALLMARK_INFLAMMATORY_RESPONSE 9.16E-06 3.07E-11 1.13E-19 4.08E-25 8.69E-23
HALLMARK_ANGIOGENESIS 1.06E-05
HALLMARK_COAGULATION 1.77E-05 1.90E-23
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 3.20E-05 4.76E-13 1.13E-19 1.52E-18 3.09E-21
HALLMARK_INTERFERON_ALPHA_RESPONSE 1.26E-12
HALLMARK_HYPOXIA 1.26E-12 3.81E-20 3.38E-25
HALLMARK_MYOGENESIS 1.26E-12
HALLMARK_G2M_CHECKPOINT 3.07E-11 1.50E-36 1.96E-24
HALLMARK_TNFA_SIGNALING_VIA_NFKB 4.32E-09 2.37E-30 6.38E-26
HALLMARK_E2F_TARGETS 1.50E-36 1.63E-20
HALLMARK_MITOTIC_SPINDLE 1.13E-19
HALLMARK_IL2_STAT5_SIGNALING 6.16E-19 1.18E-22
HALLMARK_UV_RESPONSE_DN 2.57E-17
HALLMARK_XENOBIOTIC_METABOLISM 1.54E-14
HALLMARK_COMPLEMENT 4.08E-25 9.69E-20
HALLMARK_ESTROGEN_RESPONSE_LATE 1.54E-14 5.18E-22
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evolved over time. For example, pathways representing vari-
ous metabolic processes, coagulation, apoptosis and hypoxia 
are more highly enriched late in infection (Figure 3A). These 
changes occurred concurrently with loss of red pulp/white pulp 
differentiation and the onset of extramedullary haematopoiesis 
(as evident from the abundance of splenic megakaryocytes; 
Figure 1G and H).
We next used pathway analysis to look in more detail at the 
evolution of and the main upstream regulators of the DE 
genes identified at each time point post infection. Comparative 
analysis within Ingenuity Pathway Analysis (IPA) indicated that 
IFNc, LPS, IL-1B, TLR4, TNF and STAT1 were amongst the 
highest scoring and significant upstream regulators predicted to 
be activated during infection (with activation z scores ranging 
from 2.89 to 9.5 and p values from ~10-5 to 10-48), whereas 
IL-10RA and TRIM24 were upstream regulators that were pre-
dicted to be down regulated (z scores of ~-4 to -9 and p values 
from 10-7 to 10-35; Figure 3B). It should be noted that predic-
tions made by IPA are based on the expression patterns of 
genes that are known to be regulated by different upstream 
regulators and do not require that the upstream regulator itself 
appears as DE in the data set. For example, at day 36 p.i., 
activation of IFNG was predicted by the changes in expression 
seen in 301 known IFNG target genes, consistent in this case 
with an observed Log2FC change in expression of IFNG of 
3.474. IFNG was further predicted to interact with 694 genes (or 
13.7%) of all DE genes via a mechanistic network involving 
15 other regulators (Figure 3C). Similarly, using the Interfer-
ome database which contains expression data related to ~4000 
interferon regulated genes (v2.01;46), 32.3% (1645/5096) of 
all DE genes scored as interferon inducible, of which 743 and 
431 scored as uniquely regulated by Type I and II (IFNG) 
interferons, respectively (Figure 3D). In contrast, IL-10RA and 
TRIM24 were predicted to be inhibited based on the expres-
sion change of 108 and 41 genes, respectively, although in this 
case, neither of these predicted upstream regulators was itself 
DE. The 41 genes that predict inactivation of TRIM24 during 
L. donovani infection are shown graphically according to subcel-
lular localisation in Figure 3E,. The lack of differential expres-
sion of IL-10RA and TRIM24 may reflect that function is 
not transcriptional regulated or that transcriptional regulation 
was below the Log2FC cutoff employed in this analysis (due to 
low abundance of cells expressing the gene of interest or only 
minor changes to mRNA abundance).
Finally, we examined expression of cytokine and chemokine 
genes as well as genes for their respective receptors, to provide 
a high-level view of immune pathways activated during infec-
tion in this target tissue (Figure 4). Cytokines with increased 
Figure 4. Cytokine and chemokine ligand and receptor gene expression in the spleen of mice infected with L. donovani. A–C. Heat 
maps representing Log2 fold change in mRNA abundance for chemokines, interleukins and IFNG / TNF family members and their receptors 
are shown. Only genes that were DE for at least one time point post infection are shown. Blue blocks represent down-regulated genes and 
red blocks indicate up-regulated genes. White blocks represent genes that were not significantly DE at a given time point.
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mRNA accumulation at all time points included Il10 and Il21, 
whereas for others (e.g. Il1b and Il6) there was progressive increase 
in mRNA accumulation over time. Ifnc mRNA abundance also 
increased over time post infection, whilst enhanced accumula-
tion of Tnf mRNA was observed only late in infection and other 
TNF superfamily members showed variable responses. Distinct 
temporal regulation of chemokine mRNA abundance was also 
observed. In contrast to chemokine ligands, mRNAs for many 
chemokine receptors were found at lower abundance in infected 
mice compared to controls (e.g. Ccr1 and Ccr9), and the same 
trend was also observed for some cytokine receptors, notably 
Il17rb, Il17rd and Il17re.
Comparative analysis of splenic response in mice and 
hamsters infected with L. donovani 
In contrast to murine EVL, hamsters infected with L. donovani 
develop progressive and fatal visceral leishmaniasis, provid-
ing a better model of end stage human disease. The height-
ened sensitivity of hamsters to L. donovani infection has been 
attributed, in part, to a deficiency in NOS2 production, resulting 
from a promoter polymorphism similar to that seen in humans48. 
In addition, alterations in immune response associated with 
T cell exhaustion and myeloid cell dysregulation have been 
reported based on transcriptomic as well as functional analysis41,42. 
However, a detailed comparison of the pathophysiology in 
infected hamsters and mice has not been conducted. We made 
use of recently published RNA-Seq data derived from the 
spleens of hamsters infected with L. donovani infection41 to 
compare these two infection models, albeit with the caveat that 
different technologies were used for measuring mRNA abun-
dance. Kong et al.41 observed 4360 DE transcripts at d28 post 
infection, of which 2340 (53.7%) were up-regulated and 2020 
(46.3%) were down-regulated compared to spleens from naïve 
hamsters. In comparison, in L. donovani infected mice at the 
peak of splenic infection in our study (d36 p.i.), we identified 
41.2% of DE probes as upregulated and 58.8% as down- 
regulated (Table S1). By filtering on FDR and FC (<0.05; 
>2FC), removing the bottom quartile of hamster genes that were 
expressed with a cpm of <1 and by averaging across multi-
ple probes/reads, we generated three lists of genes, those DE in 
hamster and not mouse (1504 genes), DE in mouse and not 
hamster (2239 genes) and those DE in both (485 genes, 
Figure 5A and Table S3).
Amongst common DE genes, there were those that were up 
or down consistently in both species, and in more limited 
number, some that showed differential expression in alternate 
directions (35 up in mouse and down in hamster and 37 up 
in hamster and down in mouse; Figure 5B and Table S3). To 
further examine these DE gene lists, we used STRING, a 
protein-protein interaction database45. We identified no discernible 
functional pathways associated with the small number of inversely 
DE genes. Analysis of common upregulated DE genes identi-
fied a highly significant enrichment for immune system process 
(GO:002376; FDR 7.37×10-23) and cell cycle process (GO:0022402; 
FDR 2.75×10-19) related genes that form two major clusters 
amongst all commonly upregulated genes (Figure 5C). Amongst 
common down-regulated DE genes, although there was no 
major clustering of genes there was a significant enrichment in 
GO terms related to changes in morphology, pathways 
for anatomical structure morphogenesis (GO:0009653; FDR 
3.22×10-14) and vascular development (GO:0001944; 1.82×10-11), 
the latter including negative regulators of angiogenesis such 
as Mmrn2 and promoters of angiogenesis such as Vegfa 
(Figure 5D). These data are consistent with the notion that 
the well documented changes in vasculature associated with 
murine infection9 also occur during hamster infection.
Amongst DE genes upregulated only in infected hamsters, GO 
pathways related to negative regulation (e.g. GO: 0048519; 
FDR 1.13×10-7) and immune system processes (e.g. GO:0002376; 
FDR 2.1×10-7) predominated, again forming significant cluster-
ing in the dataset (Figure 5E). Most notable amongst the top 
25 up regulated genes were Ido1, a potent negative regulator 
of immune responses (245-fold upregulated) and Arg1, associ-
ated with Th2-associated cytokines (36-fold upregulated). Sur-
prisingly, Il10 was not upregulated in splenic tissue. In contrast, 
DE genes downregulated in hamsters only related to morpho-
genesis and organismal processes (e.g. GO:0051239: FDR 
5.78×10-9), complexes of collagen trimers (GO:0098644; FDR 
3.4×10-11), drug metabolism (KEGG:00983; FDR 7.94×10-8) 
and serine proteases, trypsin domain (IPR001254; FDR 0.00741). 
Of the top 25 down-regulated genes, 10 encoded amylase 
or amylase precursor proteins and 10 have serine peptidase 
activity (Table S3).
Amongst DE genes upregulated only in murine infection, 
genes associated with GO terms related to host defence and 
immune response again predominated (e.g. GO:0006955; FDR 
2.03×10-10; GO:0006952; FDR 4.96×10-10). Notable amongst the 
top 25 upregulated genes were Ptgs2 (or Cox-2), a key enzyme 
in the pathway leading to prostaglandin synthesis (124-fold 
upregulated), Tff1, associated with chronic inflammation (75-fold 
upregulated), Ctsg, thought to promote excessive inflammation 
(33-fold upregulated) and the neutrophil related proteins Lcn2 
and Ngp (19.7 and 24.3-fold upregulated respectively). Notable 
in the top 25 downregulated genes were Cd27 (langerin; 23-fold 
downregulated), the sodium voltage gated channel encoding 
Scn3a (18-fold down regulated), Cd209c (SIGNR2; 9-fold), and 
Il22ra2, a soluble receptor that inhibits IL-22 activity (12.7-fold).
Finally, given its importance to the host response to infection, 
we examined the status of macrophage activation, and observed 
a good degree of concordance for M1-associated transcripts (as 
described in Figure 6 of 41) between hamster and mouse (55% 
of genes, including Ccl2, Cxcl9, Cxcl10, Ifng, Irf1, Irf7, Irg1, 
Socs3, Stat1 and Ccr7). In contrast, M2-associated genes were 
less commonly regulated in mouse compared to hamster spleen 
(23% of genes listed in Figure 7 of 41, including Ccl2, Cd209a, 
Cebpb, Chi3l1, and Il1rn). These data are in accord with the 
above analysis indicating an enhanced Th-2 type inflammation 
in hamster compared to murine EVL.
Hepatic response to L. donovani infection in BALB/c mice
We adopted a similar approach to examine transcriptional 
changes in the liver of L. donovani infected mice, where the 
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Figure 5. Comparison between DE genes in hamster and mouse spleen. DE genes identified in mouse spleen (d36 p.i.; this study) were 
compared to those identified in 41. A. Venn diagram showing overlap of DE genes. B. Correlation plot of Log2FC for mouse and hamster DE 
genes. C–F. STRING analysis of predicted protein interactions for DE genes identified as upregulated in both mouse and hamster (C; yellow 
= cell cycle, blue = immune response), down-regulated in mouse and hamster (D; red = anatomical structure, blue = vascular development), 
up-regulated in hamster only (E; yellow = negative regulation, blue = immune system), and down-regulated in hamster only (F; green = 
regulation of multicellular processes, red = complex of collagen fibres, yellow = drug metabolism, blue = serine proteases trypsin domain). All 
DE genes are shown on the images to provide a visual representation of the extent to which these genes are clustered into common pathways. 
For full details of all DE genes, see Table S3.
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Figure 6. Hepatic response to L. donovani infection. Livers from BALB/c mice infected with L. donovani were removed at 15-, 17-, 21-, 
36- and 42-days post infection. A. Parasite burdens were determined from impression smears and are represented as mean LDUs ± SEM. 
B. Granuloma density (mm2; green dots) and average granuloma size (µm2; yellow squares) are shown per mouse and with group mean. 
C–F. Distribution plot of granuloma size (ranging from 150 µm2 to 6140 µm2) for 15, 21, 36 and 42 days p.i. respectively. Inset shows 
representative granulomas identified using TissueQuest, with F4/80 staining (red) and attributed size in µm2. G–J. Granuloma morphology 
at 15, 21, 36 and 42 days p.i. respectively. H&E x40 magnification; scale bars 50 µm. Blue arrows indicate amastigote clusters. Dashed line 
denotes granuloma perimeter.
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Figure 7. Transcriptomic profiling of hepatic response to L. donovani infection in BALB/c mice. A. Volcano plots showing DE probes 
at each time point of infection (relative to matched naïve control mice). Data are shown as Log2 FC in expression against Log10 adjusted 
p value. B. Heat map of probe expression intensity across time series. Data are pooled for n=5 mice per group for clarity. Vertical blue trace 
indicates mean intensity signal. Sample “naïve 0” was used to calculate DE genes for days 15, 17 and 21 p.i. Samples “naïve 36” and “naïve 
42” were used to calculate DE genes for their respective time points p.i.
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process of granulomatous inflammation has been well- 
characterised at the histological level13,49,50. In contrast to the 
persistent parasite burden observed in the chronically infected 
spleen, parasite burden was significantly reduced in the liver 
by d42 p.i. (Figure 6A). This was commensurate with the devel-
opment and maturation of host protective granulomas, as indi-
cated by quantitative morphometric analysis of granuloma number 
and area (Figure 6B–F) and through observation of H&E 
stained sections (Figure 6G–J).
In the infected liver, 16192 probes were scored as DE (>2 FC, 
5% FDR) for at least one time point (Figure 7 and Table S4). 
As seen in volcano plots (Figure 7A vs Figure 2A) there was a 
tendency towards greater fold changes in mRNA accumulation 
compared to spleen with a bias towards up-regulated genes.
By GSEA, we identified 20–24 hallmark gene sets that 
were associated with infection over the time course of 
infection (using a conservative threshold of 5% FDR); these 
enriched gene sets showed a high level of concordance 
and included allograft rejection, inflammatory response, IFNG 
and IFNA signalling, TNF- , IL-2- and IL-6-related signalling 
pathways, pathways related to cell cycle, apoptosis, and com-
plement Several were also found associated with the response 
to infection in the spleen (Table 1 and Figure 8). There was, 
however, liver-specific enrichment for hallmark gene sets repre-
senting regulation of Kras signalling, epithelial and mesenchyme 
transition, angiogenesis, notch signalling and apical junction 
and apical surface. The latter are likely to reflect underlying 
changes in hepatocytes, which although not grossly abnormal in 
structure in H&E sections, may nevertheless have an important 
role in liver pathophysiology during disease51.
mRNA accumulation for genes associated with cytokines, 
chemokines and their associated receptors were also compared 
over time (Figure 9). In general, the breadth and intensity of 
response seen in the liver was greater than in the spleen, a 
result at least in part due to the greater change in cellular com-
position between resting and inflamed liver compared to rest-
ing and inflamed spleen. Nevertheless, it is also likely that some 
of the cytokine / cytokine receptor pathways that are more 
pronounced in the liver may reflect the self-cure phenotype 
associated with this organ. For example, at least at the level 
of mRNA abundance, IFNG and IL-10 are not discriminatory 
between spleen and liver, whereas early increases in mRNA 
abundance for TNF and a broad range of TNF superfamily 
members appears liver specific.  Of note, for many cytokines 
and chemokines, day 36 represented the peak of the response 
in the liver, with reduced mRNA accumulation at day 42 
associated with the reduction in parasite load seen at this time 
(Figure 6).
Finally, we examined the expression of inhibitory receptors 
associated with T cell exhaustion5,52,53, to determine whether 
expression at the whole tissue level provided any clues as to the 
rate of cure for L. donovani infection seen in these two organs 
(Figure 10). Inhibitory receptors were more prominently 
associated with the hepatic response, again likely reflecting 
the more dramatic increase in relative T cell frequency in liver 
vs. spleen. In spleen, Lag3 was the only inhibitory receptor 
that remained elevated over the entire course of infection. 
Of note, similar to mouse spleen, Lag3 was also significantly 
upregulated in hamster spleen whereas Havcr2 (Tim-3) was also 
significantly down-regulated (Table S3).
Whole blood transcriptional response to L. donovani 
infection.
As whole blood is the most accessible target tissue for transcrip-
tomic profiling in humans and previous work had suggested 
that whole blood signatures might be useful avatars of the sys-
temic response, we compared the response between spleen, 
liver and blood. 26,836 probes (12348 annotated genes) were 
identified as DE (FDR 0.05, FC2) in at least one time point 
(Table S5). By GSEA blood was, not surprisingly, more 
similar to spleen than liver (Figure 8). We next took 
advantage of a recently published whole blood transcriptomic 
analysis39 to compare responses across murine EVL and 
human VL. Using day 36-infected mice as a comparator, our 
results suggest a high divergence in whole blood response 
between EVL and human VL (Figure 11). 
Identification of common response signature in spleen, 
liver and blood during murine L. donovani infection
Finally, we asked whether it was possible to identify a com-
mon response signature found in all tissues that might act as 
a biomarker of infection and which, when measured in blood 
might reflect or predict systemic disease. When analysed for genes 
that were DE at all time points in all tissues, we did not identify 
any genes that were significantly down regulated in expression. 
In contrast, 26 genes were consistently and significantly 
up-regulated across blood, spleen and liver at all times p.i in 
murine EVL (Figure 12). These genes, of which 25/26 (96%) are 
interferon responsive, clustered in STRING analysis around 
2 nodes (Cxcl9 and Gbp1: Figure 12B and C) and reflected 
a significant enrichment for GO TERMS including “cellular 
response to interferon-beta” (GO:0035458, FDR 7.19×10-8), 
“defence response to protozoans” (GO:0042832, FDR 7.22×10-8), 
“immune response” (GO:0006955, FDR 9.71×10-8), and symbi-
ont containing vacuole” (GO:0020003, FDR 2.15×10-9). The gene 
set also contained 3 apolipoprotein L genes (Apol10a, Apol10b 
and Apol11b) which are phylogenetically related amongst 
the 12 members of the murine Apolipoprotein L family54. 
Of note, 19/26 (73%) genes in this signature were also upregu-
lated in hamster spleen (Figure 12B), whereas 6/26 (23%) 
were upregulated in human whole blood39. Common to all 
data sets were genes encoding IFNG, the CD20-like antigen 
membrane spanning 4-domains A6A (MS4A6A/Ms4a6d), and 
the interferon-inducible genes guanylate binding protein 2 
(GBP2/Gbp2), suppressor of cytokine signalling (SOCS1/Socs1) 
and tryptophanyl tRNA synthetase (WARS/ Wars).
Discussion
The immune response to L. donovani infection has been exten-
sively analysed using a wide array of technologies, including 
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Figure 8. Comparison between hepatic and splenic responses to L. donovani by GSEA. Data were subjected to GSEA with reference to 
MSigDB Hallmark gene sets and normalized enrichment score (NES) over time is shown as a heat map for significant gene sets enriched in 
liver spleen and blood at the state time points.
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Figure 9. Cytokine and chemokine ligand and receptor gene expression in the liver of mice infected with L. donovani. A–C. Heat maps 
representing Log2 fold change in mRNA abundance for chemokines, interleukins and IFNG / TNF family members and their receptors are 
shown. Only genes that were DE for at least one time point post infection are shown. Blue blocks represent down-regulated genes and red 
blocks indicate up-regulated genes. White blocks represent genes that were not significantly DE at a given time point.
Figure 10. Expression of immune checkpoint genes in the 
spleen and liver of mice infected with L. donovani. Heat map 
representing Log2 fold change in mRNA abundance for immune 
checkpoint genes in spleen and liver of L. donovani-infected BALB/
c mice. Only genes that were DE for at least one time point and at 
least one organ are shown. Blue blocks represent down-regulated 
genes and red blocks indicate up-regulated genes. White blocks 
represent genes that were not significantly DE at a given time 
point.
use of gene KO mice, advanced imaging techniques and 
cell/cytokine manipulations5,8,50,55–57. Yet a comprehensive pic-
ture of the dynamic complexity of the host response has not 
previously been reported. Here, we provide data from a detailed 
transcriptional analysis of the response of BALB/c mice to 
L. donovani infection and compare this where possible to 
existing data sets from other species, including humans. This 
high-level overview of transcriptional changes associated with 
infection poses a number of important questions and provides 
an important additional data resource for the leishmaniasis 
research community.
BALB/c mice were chosen for this study due to their extensive 
use as an immunological model of infection and as a tool for 
the pre-clinical evaluation of drugs and vaccines58–61. In this 
and most other mouse strains on a Slc11a1 (Nramp1) mutant 
background, such as C57BL/6, hepatic infection is self-resolving 
and associated with the development of granulomatous 
inflammation, whereas splenic parasite load persists, often for 
several months, accompanied by marked alterations to organ 
microarchitecture13. We selected time points when hepatic and 
splenic parasite burden were increasing and also to reflect the 
time frame over which a dichotomy in host resistance becomes 
apparent in spleen and liver. Where possible, we have also 
mined existing data to look for similarities and/or differences in 
·½»ʸʽÅ¼ʺʺ
»ÂÂ¹ÅÃ»Æ»Ä»É»·È¹¾ʹʷʸˀƑʺƓʸʺʼ·ÉÊËÆº·Ê»ºƓʷʹʹʷʸˀ
Figure 11. Comparison of whole blood transcriptome in murine EVL and human VL. A and B. Murine whole blood data from day 36 p.i. 
was re-analysed with a cut off of log2FC= 1.5 to make comparable with the human data presented in 39. Venn diagram indicates a minimal 
overlap between DE genes that are up regulated (A) and down-regulated (B) during infection. C and D. STRING analysis of the common up-
regulated (C) and down-regulated (D) genes. E and F. Most significant (by FDR) GO terms and Kegg pathways associated with mouse and 
human specific up-regulated (E) and down-regulated (F) genes, generated by STRING.
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Figure 12. A 26-gene transcriptional signature is present in blood, spleen and liver throughout the course of L. donovani infection in 
BALB/c mice. A. Venn diagram showing relationship between genes consistently up-regulated across time in blood, spleen and liver. B. Heat 
map showing expression over time for the 26 gene signature in each tissue. Data are shown as Log2FC, indicated by the scale bar. Asterisks 
denote that genes were also upregulated in the spleen of hamsters infected for 28 days (data from 41.) C. STRING analysis of the 26-gene 
signature indicates two hub genes (Cxcl9 and Gbp1) forming a network that encompasses 21/26 (81%) of these genes.
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transcriptional response. Whilst these comparisons are inform-
ative, some degree of caution needs to be exerted on their 
interpretation. Platforms used for analysis of transcriptomic 
changes differ (Agilent gene arrays, Illumina Bead Chip arrays, 
RNA-Seq), with microarrays often having more limited dynamic 
range than RNA-Seq. For this reason, we have not attempted 
any quantitative comparison in expression levels across 
platforms. Rather, our comparisons are drawn on the basis of com-
paring DE gene lists generated using standard analysis and sta-
tistical tools suited for each platform. In addition, variables such 
as tissue parasite load and time of infection are difficult to 
standardise (particularly for human disease where the time of 
infection is usually unknown), and with the exception of our 
study, data is currently restricted in most species to a single tis-
sue site. It should also be remembered that whether comparing 
between tissues in the same host or across species, lists of DE 
genes may reflect changes due to either alterations in gene 
expression pattern of individual cells or due to changes in tissue 
cell composition. Although in some cases our results were unex-
pected and showed dissimilarity between experimental models 
and human disease, this should not be taken as an argument 
against the value of research in such models. Rather, it stresses 
that once proof-of-concept has been achieved in a model, 
additional validation based on human data is essential. 
Furthermore, such human data may form the basis for selecting 
an appropriate pre-clinical model for the question at hand, 
or indeed for engineering more refined models of novel aspects 
of human disease.
Splenic histopathology of infected BALB/c mice, as expected, 
indicated extensive remodelling of the splenic architecture and 
the late onset of extramedullary haematopoiesis, similar to that 
seen in other mouse strains8. Coincident with these changes, 
we observed transcriptional signatures associated with the 
activation of immune responses, angiogenesis and coagulation 
pathways. Interferon-related pathways were highly dominant. 
Approximately 13% of the identified DE genes were predicted 
to be downstream of IFNG signalling and ~30% of all genes were 
scored as interferon inducible using the Interferome database46. 
IPA identified two candidate negative regulators IL-10Ra and 
TRIM24. IL-10 signalling through IL-10Ra (CD210) is well rec-
ognised for its role in inhibiting immune clearance of Leishma-
nia in mouse models and in humans1,2,7,62–64, operating to directly 
regulate macrophage activation and also the function and devel-
opment of IL-10 producing Th1 and Tr1 cells1,63–66. Therapeutic 
interventions to target IL-10 mediated immune regulation in 
human VL have been posited67. TRIM24 is a bromodomain- 
containing transcriptional regulator protein that has recently been 
the focus of attention as a regulator of STAT3 recruitment dur-
ing oncogenesis68 and as a positive regulator of Th2 cytokine 
production in Th2 cells69. The predicted inhibition of TRIM24 
would, therefore, be consistent with a dominant Th1 type immune 
response during murine EVL. TRIM24 is also observed as 
a target for inactivation during infection with lab-adapted 
H1N1influenza A virus70 and has been shown to be targetable 
using novel heterobifunctional protein degraders71, suggest-
ing that pathways controlled by TRIM24 could be further 
manipulated in favour of host protection.
In contrast to the murine EVL model, data generated by 
Melby and colleagues suggests that the immune response in 
hamster EVL favours a more prominent Th2 like response40,41. 
In addition, their analysis also indicates that macrophages in 
hamster EVL are conditioned to respond to activation with the 
induction of a program of gene expression that favours amastig-
ote growth, including Arg1, Ido-1 and Irg1 and associated with 
STAT3 activation41. At the peak of splenic infection in our 
study (d36 p.i.), which we considered the best approximation of 
the hamster model that we could achieve based on the degree of 
pathology, we did not observe increased accumulation of Ido1 in 
murine EVL and a comparison of signature M1 and M2 genes 
suggested that in murine EVL, M1 activation was favoured. At 
a tissue level, alternate regulators of inflammation such as 
Ptsg2 and Il-10 appeared to be favoured in murine EVL. 
Upregulation of Ptsg2 (Cox2) is consistent with the enhanced 
production of prostaglandins in spleen cells from mice with 
L. donovani infection72 and with the host protective effect of 
Cox2 inhibition in vivo73.
There has been considerable recent interest in the poten-
tial for host-directed therapies in different forms of 
leishmaniasis4,5,67,74–77. Of interest, therefore, is how well 
pre-clinical models may predict novel approaches applicable to 
human VL. Our analysis showing increased mRNA abundance 
for a variety of checkpoint inhibitors including CTLA4, PD1, 
LAG3 and others (Figure 10) supports the notion that these may 
be candidates for the development of immunotherapy, along 
with key suppressive cytokines like IL-10. In the mouse, these 
checkpoint inhibitors (along with many cytokines, chemok-
ines and their receptors) have a complex pattern of temporal 
and tissue-specific regulation which, together with the potential 
for cell migration between sites, makes predictions concern-
ing the impact of immunotherapy challenging. Some of these 
checkpoint targets are equally represented in mouse and ham-
ster spleen and human whole blood e.g. LAG3 and CTLA4, 
whereas others show species restricted regulation. For exam-
ple, IDO-1 is up regulated in hamster spleen and human whole 
blood, but not in any mouse tissue examined. Importantly, these 
diverse data as well as the clear dichotomy of expression at 
a tissue specific level, indicate the need to build a more 
comprehensive and uniform knowledge base regarding these 
pathways in different models and forms of human disease.
Analysis of whole blood has been a valuable tool for 
monitoring transcriptional changes associated with infection 
and even for predicting drug efficacy19, but the relationship 
between transcriptomic changes in blood and tissue remains 
poorly understood. Pooling data across all tissues and time points, 
we were able to identify a 26-gene signature that was com-
mon to spleen, liver and blood during murine VL. 96% of these 
genes have been reported as interferon inducible, clearly indicat-
ing the dominant nature of interferon signalling during murine 
VL and that this common signature reflects disease in all organs/ 
tissues studied. The value of defining signatures of this type 
might be to understand common pathways underlying inflam-
mation or to provide new biomarkers that reflect the level of 
ongoing systemic disease that can be monitored in blood. We 
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will further elaborate on the use of this signature to evaluate 
chemotherapy induced cure in murine VL in a subsequent manu-
script (Forrester et al. manuscript in preparation). The clinical 
value of this signature is however questionable at this stage, 
given the lack of similarity between whole blood transcriptomic 
responses observed in our study and that of humans with VL 
in Brazil39. In a similar study in acute melioidosis, 26.9% 
of genes were similarly regulated in murine and human 
infection21. The reasons for this lack of similarity in VL are 
likely to be multiple, including the chronicity of infection, 
difference in pathogen (L. donovani vs. L. infantum), spe-
cific characteristics of Brazilian VL compared to VL on other 
continents12 or differing analytical methods. It would be inform-
ative, given the above discussion, to compare human whole 
blood from a greater range of patient populations with VL to 
better understand the extent of temporal and geographic diver-
sity in the transcriptome of patients with VL. Likewise, data on 
hamster whole blood might help ascertain whether the blood 
transcriptome in this model more closely resembles that found 
during human disease.
Finally, a deeper understanding of subtleties of the immun-
opathology of leishmaniasis in different target tissues (e.g. 
granulomatous vs. non-granulomatous) and their relation-
ship to gene transcriptional changes will require more in-depth 
analysis than that reported here, using new techniques to inte-
grate image analysis with complex “omics” and other meta data. 
Such approaches are fuelling significant advances in precision 
medicine in other fields, notably cancer and neuroscience78–80, 
but have to date had limited application in the field of infec-
tious disease. To facilitate the development of such approaches 
in leishmaniasis, we have generated a digital whole slide collec-
tion of the tissue sections generated in this study, stained with 
both H&E and markers to identify myeloid cells (F4/80 and 
1A8). These are available via a new network designed to sup-
port the development of digital pathology in leishmaniasis 
(www.leishpathnet.org), and improve transparency and data 
sharing. In addition, the data collected from the animals used in 
this study forms part of a larger program of work (the CRACK 
IT Virtual Infectious Diseases Research Challenge; https://crackit.
org.uk/challenge-16-virtual-infectious-disease-research) that had 
the goal of generating an in silico model of the immune response 
during murine EVL, with the aim of reducing the number of 
animals required for basic research on immune regulation 
and for evaluating potentially novel therapeutic interventions 
(www.leishsim.org). Future manuscripts from the CRACK 
IT program will extend the transcriptomic analysis presented 
here to include comparative studies with L. infantum infection, 
the response of L. donovani-infected BALB/c mice to 
chemotherapy, and the response to L. donovani infection in 
C57BL/6 (B6) and B6.Rag1-/- mice.
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Table S1. 9634 DE probes across time course of L. donovani infection in the spleen of BALB/c mice. Sheet 1 provides the list of 
9634 DE probes identified on the basis of FDR of 0.05 and a FC of 2 for at least one infection time point vs naïve control. Sheet 2 
provides the collapsed 5096 DE gene list. Expression data are shown as Log2FC.
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Table S2. GSEA analysis of DE genes in the spleen of L. donovani infected BALB/c mice. Data in the Summary tab was used to 
generate Table 1 and Figure 3A.
Table S3. Lists of annotated DE genes in mouse and hamster spleen following L. donovani infection. Gene lists are arranged as 
DE in both hamster and mouse, hamster DE only and mouse DE only. Expression data are shown as log2FC.
Table S4. 16192 DE probes across time course of L. donovani infection in the liver of BALB/c mice. Sheet 1 provides the list of 
16192 DE probes identified on the basis of FDR of 0.05 and a FC of 2 for at least one infection time point vs naïve control. Sheet 2 
provides the collapsed 8033 DE gene list. Expression data are shown as Log2FC.
Table S5. 28636 DE probes across time course of L. donovani infection in the blood of BALB/c mice. Sheet 1 provides the list of 
28636 DE probes identified on the basis of FDR of 0.05 and a FC of 2 for at least one infection time point vs naïve control. Sheet 2 
provides the collapsed 12348 DE gene list. Expression data are shown as Log2FC. Sheet 3 contains DE genes identified by Gardinassi 
et al. from whole blood of VL patients39.
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